BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gerum S, Jensen AD, Roeder F. Stereotactic body radiation therapy in patients with hepatocellular carcinoma: A mini-review. World J Gastrointest Oncol 2019; 11(5): 367-376 [PMID: 31139307 DOI: 10.4251/wjgo.v11.i5.367] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Mortensen HR, Villadsen GE, Worm ES, Weber B. Survival and morbidity following stereotactic radiotherapy of hepatocellular carcinoma: a ten-year, single institution experience. Scand J Gastroenterol 2021;56:259-65. [PMID: 33430663 DOI: 10.1080/00365521.2020.1869822] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Lam T, Wong W, Lee C, Cheung C. Transarterial chemoembolisation plus stereotactic body radiotherapy as conversion therapy for large right lobe hepatocecullar carcinoma. Surgical Practice 2021;25:211-7. [DOI: 10.1111/1744-1633.12530] [Reference Citation Analysis]
3 English K, Brodin NP, Shankar V, Zhu S, Ohri N, Golowa YS, Cynamon J, Bellemare S, Kaubisch A, Kinkhabwala M, Kalnicki S, Garg MK, Guha C, Kabarriti R. Association of Addition of Ablative Therapy Following Transarterial Chemoembolization With Survival Rates in Patients With Hepatocellular Carcinoma. JAMA Netw Open 2020;3:e2023942. [PMID: 33151315 DOI: 10.1001/jamanetworkopen.2020.23942] [Reference Citation Analysis]
4 Shampain KL, Hackett CE, Towfighi S, Aslam A, Masch WR, Harris AC, Chang SD, Khanna K, Mendiratta V, Gabr AM, Owen D, Mendiratta-Lala M. SBRT for HCC: Overview of technique and treatment response assessment. Abdom Radiol (NY) 2021;46:3615-24. [PMID: 33963419 DOI: 10.1007/s00261-021-03107-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Padgett KR, Simpson G, Asher D, Portelance L, Bossart E, Dogan N. Assessment of online adaptive MR-guided stereotactic body radiotherapy of liver cancers. Physica Medica 2020;77:54-63. [DOI: 10.1016/j.ejmp.2020.07.027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Gerum S, Heinz C, Belka C, Walter F, Paprottka PM, De Toni EN, Roeder F. Stereotactic body radiotherapy in patients with hepatocellular carcinoma in a multimodal treatment setting. Strahlenther Onkol 2020;196:334-48. [DOI: 10.1007/s00066-019-01540-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
7 Chen LC, Lin HY, Lee MS, Chiou WY, Huang LW, Chew CH, Hsu FC, Hung SK. Effectiveness of individual audio-visual coaching, respiratory modulated stereotactic body radiotherapy for localized hepatocellular carcinoma: Analysis of 29 cases from a single academic radiotherapy center. Tzu Chi Med J 2021;33:380-7. [PMID: 34760635 DOI: 10.4103/tcmj.tcmj_247_20] [Reference Citation Analysis]
8 Walter F, Nierer L, Rottler M, Duque AS, Weingandt H, Well J, Shpani R, Landry G, Seidensticker M, Streitparth F, Ricke J, Belka C, Corradini S. Comparison of liver exposure in CT-guided high-dose rate (HDR) interstitial brachytherapy versus SBRT in hepatocellular carcinoma. Radiat Oncol 2021;16:86. [PMID: 33957941 DOI: 10.1186/s13014-021-01812-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Wang F, Numata K, Takeda A, Ogushi K, Fukuda H, Hara K, Chuma M, Eriguchi T, Tsurugai Y, Maeda S. Safety and efficacy study: Short-term application of radiofrequency ablation and stereotactic body radiotherapy for Barcelona Clinical Liver Cancer stage 0-B1 hepatocellular carcinoma. PLoS One 2021;16:e0245076. [PMID: 33400718 DOI: 10.1371/journal.pone.0245076] [Reference Citation Analysis]
10 Donisi C, Puzzoni M, Ziranu P, Lai E, Mariani S, Saba G, Impera V, Dubois M, Persano M, Migliari M, Pretta A, Liscia N, Astara G, Scartozzi M. Immune Checkpoint Inhibitors in the Treatment of HCC. Front Oncol 2020;10:601240. [PMID: 33585218 DOI: 10.3389/fonc.2020.601240] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
11 Hilal L, Reyngold M, Wu AJ, Araji A, Abou-Alfa GK, Jarnagin W, Harding JJ, Gambarin M, El Dika I, Brady P, Navilio J, Berry SL, Flynn J, Zhang Z, Tuli R, Zinovoy M, Romesser PB, Cuaron JJ, Crane CH, Hajj C. Ablative radiation therapy for hepatocellular carcinoma is associated with reduced treatment- and tumor-related liver failure and improved survival. J Gastrointest Oncol 2021;12:1743-52. [PMID: 34532124 DOI: 10.21037/jgo-21-116] [Reference Citation Analysis]
12 Du S, Chen G, Yuan B, Hu Y, Yang P, Chen Y, Zhao Q, Zhou J, Fan J, Zeng Z. DNA sensing and associated type 1 interferon signaling contributes to progression of radiation-induced liver injury. Cell Mol Immunol 2021;18:1718-28. [PMID: 32203191 DOI: 10.1038/s41423-020-0395-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]